Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Príomhchruthaitheoirí: Qiao Liu (Údar), Zhen Zhou (Údar), Xia Luo (Údar), Lidan Yi (Údar), Liubao Peng (Údar), Xiaomin Wan (Údar), Chongqing Tan (Údar), Xiaohui Zeng (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...